Epratuzumab
As of the edition of 20 October 2026, Epratuzumab is an antibody: went quiet in 2017; acts on CD22.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2017
- Kind
- Antibody
- Registered trials
- 28, 8 stopped early
- Disease areas
- Immune system; Blood and lymph; Cancer; Skin and connective tissue; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route A because of this drug.
Companies on route A for this drug
In the product3 companies are on route A because of Epratuzumab.
See the 3 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD22 | B-cell receptor CD22 | P20273 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 20 | 12 | 0 | 6 |
| Phase 3 | 6 | 3 | 0 | 2 |
| All trials | 28 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Lead sponsor of trials | 2000 to now |
| UCB | Lead sponsor of trials | 2005 to now |
| Amgen | Lead sponsor of trials |